glioma, IL-4, 10-gene signature, prognosis, microenvironment, recurrence, programmed cell death 1 receptor, programmed death-ligand 1, therapeutics, hypofractionated stereotactic radiotherapy, recurrent high-grade glioma, salvage treatment, anlotinib, glioblastoma, high-grade gliomas, phosphatase and tensin homolog, PTEN, temozolomide, The Cancer Genome Atlas, TRP family genes, immunotherapy, bioinformatics analysis, PTPRN, immune infiltration, biomarker, tumor microenvironment, polystyrene nanoparticles, neurotoxicity, autophagy, mitochondrial oxidative stress, necroptosis, machine learning algorithms, single-cell analysis, immune microenvironments, RCAS-tva, rodent glioma models, metabolism, multiparametric PET/MR imaging, model characterization, PDGFB, irreversible electroporation, apoptosis, regulatory cell death, AP-1, FOS, JUN, Bim, Medical equipment and techniques

Despite the past two decades of research progress, glioma still remains the most challenging of all primary central nervous system (CNS) tumors. The complexity of its pathogenesis makes the disease hard to deal with, especially glioblastoma multiforme (GBM, WHO grade IV), the most aggressive brain tumor entity. This Special Issue collect studies that focus on the pathogenesis of glioma, such as its cell origin, the role of GSCs, genomic alterations, animal models, etc. We have collected 10 high-quality papers, and we welcome all researchers to read.